Abstract Background: Asparagine synthetase deficiency (ASD) is a newly identified neurometabolic disorder characterized by severe congenital microcephaly, severe global developmental delay, intractable seizure disorder, and spastic quadriplegia. Brain MRI showed brain atrophy, delayed myelination, and simplified gyriform pattern.
Introduction
Asparagine synthetase deficiency (ASD) is a new rare autosomal recessive neurometabolic disease which is caused by homozygous or compound heterozygous mutation in the ASNS gene on chromosome 7q21 (Ruzzo et al. 2013) . It is described recently by Ruzzo et al. (2013) who reported nine cases from four unrelated families; they have a distinct form of severe encephalopathy associated with congenital microcephaly, progressive brain atrophy, intractable seizure, and profound developmental delay (Ruzzo et al. 2013) . They had axial hypotonia with severe appendicular spasticity (Bourgeron et al. 1994; Ruzzo et al. 2013) . As this is a newly described disease, there is not much data about clinical and biochemical phenotype. In this case report, we elaborate more on the clinical, biochemical, and molecular findings of 2 siblings with asparagine synthetase deficiency and we compared our results to the previously reported cases. To the best of our knowledge, this is the first time in the literature that confirmed low CSF asparagine in this disorder and the third report in the literature regarding this new inborn error of neurometabolic disorder.
Case Report
Patient 1 was a full-term baby boy born by cesarean section due to fetal distress and failure to progress to the firstcousin Saudi parents. His birth weight was 3.1 kg (10-25th percentile), length 45 cm (<5th percentile), head circumference 30 cm (<5th percentile), and Apgar score 8 and 9 at 5 and 10 min, respectively. Few hours after birth, he started to have intractable seizure. He stayed in the nursery for 6 days with myoclonic seizures until controlled with multiple antiepileptic medications. Then he was discharged on these medications and continued to have an on-and-off attack of myoclonic seizure. On examination, his growth parameters continued to be less than 5th percentile and growth arrested.
Electroencephalogram (EEG) showed multifocal epileptiform discharges, diffuse slowing, and paroxysmal attenuation in sleep. Brain MRI showed severe microcephaly, brain atrophy, evidence of simplified gyral pattern, and delayed myelination (Fig. 1) . Modified barium swallow showed minimal laryngeal penetration without aspiration. Upper GI study showed moderate to severe reflux with no malrotation.
Patient 2 was the sister born by normal spontaneous vaginal delivery. Her birth weight was 2.65 kg (below 10th percentile) and the head circumference was 26.5 cm (far below 5th percentile) and length was 42 cm (below 10th percentile). Apgar scores were 7 and at 1 min and 8 at 5 min. She was admitted to NICU after 5 min of age with severe microcephaly and seizure and she has the similar course and clinical phenotype as her brother.
On examination of both siblings at 2 and 4 years of age, both have severe microcephaly and all growth parameters <3rd percentile. They have subtle dysmorphic features (microcephaly, brachycephaly, pear-like head shape, micrognathia). Neurological examination showed axial hypotonia and appendicular hypertonia with hyperreflexia ( Fig. 2) . They continued to have severe developmental delay and not acquiring any milestones. Other system examinations were unremarkable. Both continued to have intractable seizure refractory to antiepileptic medications. Milk scan showed recurrent gastroesophageal reflux.
All biochemical and molecular investigations including acylcarnitine profile and urine organic acids, creatine kinase (CK) level, total homocysteine, lactic acid, ammonia level, chromosomal analysis, and CGH microarray were unremarkable. The concentration of CSF neurotransmitters homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) was moderately reduced. Molecular genetic testing of MC2R, PNKP, and ASPM was negative.
Further analysis by whole exome sequencing (WES) performed on both siblings and parents identified a previously unreported homozygous mutation in exon 10 of the asparagine synthetase (ASNS) gene (c.1160A>G[p. Tyr377Cys]) in both siblings. The parents confirmed to be carriers for this mutation and the discovered mutation validated by Sanger sequencing methodology (for detailed WES methodology, filtering strategy, and average coverage, please see supplementary materials).
Discussion
Our report showed the similar findings delineated by previous reports (Ruzzo et al. 2013; Ben-Salem et al. 2014) . Table 1 compared the clinical findings in this report with the former ones. In 12 children described so far, all has the following cardinal features which are severe congenital microcephaly (100%), ranging between 26.5 and 31.5 cm; severe developmental delay and the patients just lying in the bed, not fixing or following and not acquiring any milestones; appendicular hypertonia; and hyperreflexia (100%). Majority of patients has additional clinical features including intractable seizure (9/12, 75%), axial hypotonia (8/12, 67%), and hyperekplexia (3/12, 25%). The type of seizure is not specific including myoclonic, tonic, spasm, and generalized tonic-clonic seizure which are refractory to antiepileptic medications. EEG pattern is reported differently but with main features such as multiple independent spike foci (8/12, 67%); other EEG findings were hypsarrhythmia, burst suppression, disorganized background. Radiologically, all patients have severe microcephaly, brain atrophy, and delayed myelination (100%). Other features include simplified gyriform pattern (9/12, 75%) and decreased size pons (7/12, 58%) (Fig. 2) . The consanguinity found in 4/6 families (67%) suggests that this disorder is inherited as autosomal recessive pattern. Furthermore, the ethnicities are diverse including Iranian Jews, French Canadian, Bangladeshi, and Saudi Arabian in this report confirming that this disorder is pan-ethnic. In this report, we presented a novel missense mutation that was not described by previous reports in exon 10 of the ASNS gene. The pathogenicity and functional impact of this novel variant is supported by SIFT and MutationTaster software analyses. Furthermore, it is located in a moderately conserved nucleotide and highly conserved amino acid position, with large physiochemical differences between the amino acids tyrosine and cysteine. In addition, mutationspecific testing in both parents confirmed carrier status.
Biochemically, asparagine synthetase also known as aspartate-ammonia ligase, symbolic as ASNS, is an enzyme involved in the biosynthesis of asparagine from aspartate through an ATP-dependent transaminated reaction (Zhang et al. 1989 ). This conversion takes place in the presence of glutamine which acts as amino group donor in reaction ( Fig. 3) (Zhang et al. 1989; Ruzzo et al. 2013 ). This suggested that asparagine would be low in body fluids if this enzyme is deficient and more specifically in the brain as ASNS is highly expressed in adult brain (Hongo et al. 1996; Ruzzo et al. 2013 ) Although this was not demonstrated by the Ruzzo et al. (2013) report because the CSF Fig. 3 Asparagine synthetase enzyme converts aspartate to asparagine in the presence of glutamine which is the amino group donor in this reaction asparagine was not measured in their patients, our findings support this theory as CSF asparagine levels were low in both siblings. Plasma asparagine levels were low in the presented cases but were only low in 2/5 of previous patients (Table 2) . ASD is one of aminoacidopathies that will be an another example which illustrate the principle of mechanism of occurring the inborn errors of metabolism which are either due to accumulation of substrate or deficiency of product or transport defect (Scriver 2001) . Therefore, it will be added to other synthesis defects like creatine deficiency syndromes (Stockler et al 1994) , glutamine synthetase deficiency (Haberle et al 2005) , and the serine synthetic defects (van der Crabben et al. 2013) . In all aforementioned disorders, the treatment is the administration of the deficient product to the affected individuals and the response was variable. It will be exciting to see the response of the patients with ASD to asparagine replacement; however, given that the phenotype is present since birth, it makes difficult to predict that such treatment will be curative (Ruzzo et al. 2013 ).
In conclusion, we alert the clinicians to consider ASD deficiency in any child presented with congenital microcephaly, epileptic encephalopathy and severe developmental delay. For the first time in the literature, our report confirms low CSF asparagine level in patients with ASD deficiency.
Take-Home Message
Asparagine synthetase deficiency is characterized by severe congenital microcephaly followed by childhood global developmental delay, central hypotonia, spastic quadriplegia and intractable seizure disorder. CSF asparagine level is low in this disorder while plasma may be low. Brain MRI showed microcephaly, brain atrophy, and delayed myelination and simplified gyriform pattern.
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